EL ELV Elevance Health Loading... : Bullish and Bearish Analyst Opinions

Anthem is high-beta onchain expression.

Group life mortality runs well below target due to favorable working-age population mortality, but management flagged 2 points as transient prior-period development and expects normalization—early July shows reversion. — If mortality normalizes, insurers pricing off pandemic-era improvement face margin compression, while managed care beneficiaries (elderly) may see divergent trends.

Elevance's new coverage for Alzheimer's biomarkers expands reimbursed test volume for Quest, though AB4240 is not yet covered.

Premarket movers report shows ASML up 3% on raised forecast, BlackRock up 4% on record inflows.

US pre-market movers report shows ASML up on earnings beat, PayPal surging on acquisition offer.

Elevance Health reported second quarter operating revenue of 49.8 billion dollars and raised.

Elevance Health reports second quarter adjusted earnings per share of 7.45 dollars beating.

Elevance Health reports Q2 2026 adjusted EPS of 7.45 dollars beating estimates and reaffirms.

Elevance Health raised guidance and expressed confidence in sustained earnings growth, driven by disciplined execution across diversified lines of business and targeted investments in cost management capabilities.

The author explicitly advises selling ELV to lock in gains, implying a short-term bearish view on the stock with no further reasoning.

Author explicitly recommends selling/taking profits on ELV, implying a bearish near-term view or that the stock has reached its target.

CVS's Health Services segment pulled forward value from Q2 into Q1, masking some of the underlying rebate guarantee pressure, though the underlying business still modestly beat expectations. — Indicates timing dynamics within PBM earnings and the ongoing financial impact of rebate reform and transparency agreements.

Management raised full-year EPS guidance based on strong Q1 results and expressed confidence in 2027 growth trajectory, signaling improving operational execution and cost management.

Short ELV as McCullough explicitly discloses an active.

Under my plan, I want to stop all payments to big insurance companies and instead give the money directly to the people so that they can buy their own healthcare. Managed care organizations derive a massive portion of their revenue and earnings from government-sponsored programs, including ACA subsidies, Medicare, and Medicaid. Cutting off direct federal payments to these insurers would severely compress their margins, disrupt their revenue base, and force a complete restructuring of the health insurance market. SHORT. The administration is actively targeting the profitability and government funding mechanisms of major managed care companies. Congress blocks the proposed healthcare overhaul, maintaining the status quo for managed care revenues and government subsidies.

Bought 3,000 shares @ $289.84

Trump attacks the Affordable Care Act, stating he wants to "stop all payments to big insurance companies" and notes that "insurance companies own Democrats." He also touts "Most Favored Nation" clauses dropping drug prices by 80%. The removal of federal subsidies/payments is a direct hit to the revenue of managed care organizations (UnitedHealth, Humana). Simultaneously, aggressive price controls on drugs compress margins for the broader healthcare/pharma sector. SHORT Managed Care and Big Pharma. Congressional gridlock preventing the removal of subsidies.

Schneider explicitly highlights the "extension of the premium tax subsidies" as a priority, warning that without it, "millions of families are seeing their insurance increase by $1,500 a month." These subsidies (enhanced ACA tax credits) are direct revenue drivers for Managed Care Organizations (MCOs) focused on the exchange market. Schneider's push indicates that Democrats will make extending these credits a non-negotiable condition in budget talks. If extended, enrollment numbers for Centene, Molina, and others remain robust; if they lapse, churn increases and revenue drops. LONG. The political pressure to avoid an $18k/year cost spike for voters is high, favoring an eventual extension which benefits ACA-heavy insurers. Republican opposition to "pandemic-era" subsidy extensions could lead to a lapse, crushing margins for exchange-focused insurers.

The President intends to "codify his health care framework that seeks to shift federal subsidies from health care companies to U.S. consumers." Managed Care Organizations (MCOs) and insurers rely heavily on government subsidies (particularly in Medicare Advantage). Shifting these funds directly to consumers bypasses the insurers, threatening their margins and revenue models. SHORT. This represents a structural change to healthcare funding flows detrimental to intermediaries. The complexity of healthcare reform often leads to watered-down implementation.

"I want to stop all payments to big insurance companies and instead give that money directly to the people... stock prices soared... like nothing else." The administration views the "middleman" model of Managed Care Organizations (MCOs) as the primary driver of healthcare inflation. Shifting federal subsidies (ACA/Medicare) directly to patients bypasses the insurers, threatening their revenue streams and margin compression. SHORT. The political target on the back of the insurance sector is now explicit policy. The lobby for healthcare insurers is powerful; implementation of direct payments may face logistical gridlock.

Under the "No Surprises Act," insurers are losing over 80% of arbitration cases to providers regarding out-of-network bills. This creates a structural headwind for margins as insurers are forced to pay higher rates than anticipated. Additionally, the State of the Union address is expected to target insurer profitability and affordability, adding headline risk. WATCH / AVOID. Regulatory relief or changes to the arbitration process could alleviate cost pressures.

Re-inclusion in Elevance's networks is driving volume share gains, positive for Quest's organic growth trajectory in those states.

Management is cautious about 2026, framing it as a trough year with disciplined actions, but expresses confidence in returning to at least 12% EPS growth in 2027, indicating a neutral-to-cautiously-optimistic tone.

The administration proposed a "0.09% next year" payment increase. Holz notes investors were "positioning long thinking this was going to be a turnaround year," but now we are entering a "pocket now for a year, maybe two, in which earnings don't expand or grow." The macro environment for government-sponsored healthcare has shifted from a growth story to a stagnation story. While the stocks have dropped 20%, the fundamental driver for stock price appreciation (earnings growth) has been removed for the medium term. Buying the dip is premature because the capital will be tied up in a sector with no catalyst for 12-24 months. Do not buy the dip yet. The thesis has shifted from "turnaround" to "stagnation." The final ruling in April could be revised upward significantly, causing a relief rally (short squeeze).

UnitedHealth's membership contraction plans are significant: a loss of 1.3M-1.4M Medicare Advantage members and 565K-715K Medicaid members, totaling a 2.3M-2.8M decrease across its book. This is due to intentional repricing and state funding shortfalls. — This signals that the managed care industry is entering a period of deliberate de-growth to stabilize margins. It will likely intensify competition for remaining members and pressure healthcare providers that rely on high MA volume.

Quest regained network status with a major health plan, driving volume recovery in those states.

Management reaffirms 2025 EPS but warns of Medicaid margin deterioration and investment spending in 2026, creating a cautious near-term outlook.

Observes delayed 3% jump in price

MFN price cap would reduce insurer expenses